Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: 1.All individuals above 18 years of age with histologically confirmed HER2 positive breast cancers who received neoadjuvant chemotherapy during the period of January 2014 to December 2018. 2.Patients who have received even 1 cycle of treatment in the neoadjuvant setting will be included in the analysis. 3.Patients who have received one or more of the following treatments as part of neoadjuvant treatment will be included in the study: chemotherapy and/or HER2targeted therapy. 4.Patients with Stage 1 to Stage 3 breast cancer (AJCC 7th edition 2010) will be included in the analysis
Exclusion criteria
Exclusion criteria: 1.Individuals with HER2 positive breast cancers who did not receive neoadjuvant therapy for any reason 2.Upfront metastatic HER2 positive breast cancers 3.Individuals with other coexistent malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the impact of chosen covariates on disease free survival (DFS) in patients with HER2 positive breast cancers who achieve pathological complete response after neoadjuvant chemotherapy.Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To evaluate impact of chosen covariates on DFS in patients with HER2 positive breast cancers who do not achieve pCR after NACT 2.To evaluate the impact of chosen covariates on (OS) in patients with HER2 positive breast cancers who achieve pCR after NACT. 3.To evaluate impact of chosen covariates on OS in patients with HER2 positive breast cancers who do not achieve pCR after NACT. 4.To evaluate the impact of chosen covariates on the achievement of pCR in the collected dataset. Timepoint: 1 year from the date of starting treatment | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Centre
Outcome results
None listed